Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Jun;97(26):e11251.
doi: 10.1097/MD.0000000000011251.

Association between RAD51 135 G/C polymorphism and risk of 3 common gynecological cancers: A meta-analysis

Xianling Zeng  1 , Yafei Zhang, Lei Yang, Huiqiu Xu, Taohong Zhang, Ruifang An, Kexiu Zhu
Affiliations
Review

Association between RAD51 135 G/C polymorphism and risk of 3 common gynecological cancers: A meta-analysis

Xianling Zeng et al. Medicine (Baltimore). 2018 Jun.

Abstract

Aim: Available data concerning the association between RAD51 135G/C (rs1801320) polymorphism and the risk of 3 common gynecological cancers still could not reach a consensus. Thus, we conducted a meta-analysis to explore the relationship.

Methods: Several electronic databases and bibliographies of relevant articles were screened to identify the studies up to July 2017. Then a meta-analysis was performed to evaluate the connection between 3 common gynecological tumors' susceptibility and RAD51 135G/C polymorphism in different inheritance models. Simultaneously, we did subgroup analysis and sensitivity analysis if necessary.

Results: A total of 11 articles including 14 studies involving 4097 cases and 5890 controls were included in this meta-analysis. Overall, RAD51 135G/C polymorphism increased the risk of 3 common gynecological tumors. The subgroup analysis stratified by cancer types- endometrial carcinoma (EC) and ovarian cancer (OC)-showed that RAD51 135G/C polymorphism increased the risk of EC: allele model (C vs G: odds ratio [OR] = 4.32, 95% confidence interval [CI] = 2.63-7.10, P < .00001), dominant model (CC + GC vs GG: OR = 2.28, 95% CI = 1.44-3.60, P = .004), recessive model (CC vs GC + GG: OR = 10.27, 95% CI = 14.71-22.38, P < .00001), and homozygous model (CC vs GG: OR = 7.26, 95% CI = 3.59-14.68, P < .00001), but there was no significant association between RAD51 135G/C polymorphism and OC. In the subgroup analysis stratified by source of controls, a significantly increased risk was observed in hospital-based studies. Nevertheless, the data showed RAD51 135G/C polymorphism had no link in population-based studies.

Conclusions: This meta-analysis suggested that RAD51 135G/C polymorphism was a risk factor for the three common gynecological tumors, especially for EC among hospital-based populations.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Search flow diagram.
Figure 2
Figure 2
Meta-analysis of association between RAD51 135 G/C polymorphism and the risk of three common gynecological cancers. CI = confidence interval, OR = odds ratio. A, Dominant model, (B) recessive model, (C) homozygous model, and (D) dominant model.
Figure 3
Figure 3
Sensitivity analysis of the association between RAD51 135 G/C polymorphism and the risk of three types of common gynecological cancers in homozygous model.
Figure 4
Figure 4
Publication bias was assessed by Begg funnel plot and Egger's plot (P > .05).
See this image and copyright information in PMC

References

    1. Goode EL, Ulrich CM, Potter JD. Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomark Prev 2002;11:1513–30. - PubMed
    1. Qiao GB, Wu YL, Yang XN, et al. High-level expression of Rad51 is an independent prognostic marker of survival in non-small-cell lung cancer patients. Br J Cancer 2005;93:137–43. - PMC - PubMed
    1. Cheng D, Shi H, Zhang K, et al. RAD51 Gene 135G/C polymorphism and the risk of four types of common cancers: a meta-analysis. Diagn Pathol 2014;9:18. - PMC - PubMed
    1. Rollinson S, Smith AG, Allan JM, et al. RAD51 homologous recombination repair gene haplotypes and risk of acute myeloid leukaemia. Leuk Res 2007;31:169–74. - PubMed
    1. Nogueira A, Catarino R, Coelho A, et al. Influence of DNA repair RAD51 gene variants in overall survival of non-small cell lung cancer patients treated with first line chemotherapy. Cancer Chemother Pharmacol 2010;66:501–6. - PubMed